FDA's Device Review Paper Trail Heads to OMB
Published Date: 11/24/2025
Notice
Summary
The FDA is asking for public feedback on extending its 510(k) Third-Party Review Program, which lets private experts help review certain medical device applications. This program affects device makers who want faster reviews and keeps paperwork manageable. Comments are due by December 24, 2025, and the program helps speed up device approvals without extra costs to manufacturers.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Voluntary Third‑Party 510(k) Reviews
You can choose to use accredited third‑party reviewers to have certain 510(k) premarket notifications reviewed. Participation is voluntary; accredited reviewers will review a manufacturer's 510(k) and forward the submission plus their documented review and recommendation to FDA, providing an alternative review path intended to let FDA focus on higher‑risk devices and help speed device review for eligible manufacturers.
Time Burdens for 3PROs and Accreditation
If you are a third‑party review organization, FDA estimates an initial accreditation request takes 40 hours (updated from 24 hours, an increase of 15 hours), re‑recognition requests 24 hours, and each 510(k) review by a 3PRO averages 40 hours. FDA estimates total annual reporting burden of 5,152.25 hours and total annual recordkeeping burden of 1,287 hours; reviewers should usually keep 510(k) review records for 3 years.
Eligibility Limits: Class I and II Device Types
Under section 523 of the FD&C Act and FDA guidance, FDA will identify which class I or class II device types, or subsets of those types, are eligible for review by an accredited person. The guidance describes the factors FDA will use to determine eligibility for third‑party 510(k) review.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-20771 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Emergency Use Authorization of Medical Products
The FDA is asking for public feedback on their paperwork for emergency use authorizations (EUAs) of medical products, like vaccines or treatments used during health emergencies. This helps keep the process smooth and up-to-date without adding extra costs or delays. Comments are open until December 24, 2025, so anyone involved in medical product development or emergency response should take note!
Next: 2025-20773 — Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act
The FDA wants your thoughts on how they collect info about making special human drugs under sections 503A and 503B. This affects pharmacies and drug makers who customize medicines for patients. Comments are open until January 23, 2026, so speak up now—this could shape paperwork and processes, but no new fees are mentioned.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in